Skip to content
Forest Global Training Partners
Home Services AI Governance AI Risk Encyclopedia Contact Us
AI Risk Encyclopedia AI Use CasesAI RisksAI Hallucinations Topics Entities Sources
  1. Home
  2. AI Risks
  3. Vertex drops asset in acute pain after phase 2 fail…

AI Risks August 05, 2025 · Fierce Biotech

Vertex drops asset in acute pain after phase 2 fail - Fierce Biotech

Vertex Pharmaceuticals Clinical Trial Results pain failed trials. Share. dart board, miss, failure VX-993 is designed to block the Nav1.8 sodium ...

Read the original at Fierce Biotech ↗

Topics
Healthcare
Tracked via
“AI Falures”

Related articles

  • HowAIAccelerates Clinical & Drug Development Timelines | Fierce Biotech AI Risks · Jun 30, 2024
  • AstraZeneca's AL amyloidosis drug fails to reduce mortality in phase 3 test - Fierce Biotech AI Risks · Jul 16, 2025
  • Merck bags options on Evaxion's AI-designed vaccine candidates - Fierce Biotech AI Use Cases · Sep 26, 2024
  • FDA approves first genetic test to screen for opioid use disorderrisks- Fierce Biotech AI Risks · Dec 21, 2023
  • Globus Medical to buy neurostim developer Nevro for $250M - Fierce Biotech AI Use Cases · Feb 11, 2025
  • Phesi CEO on why phase 3 clinical trials fail - R&D World AI Risks · Jul 31, 2025

AI Risk Encyclopedia is a curated research index from Forest Global Training Partners. Articles belong to their publishers; we link to and summarize them.

Contact